Neuphoria Therapeutics Inc. (NEUP) Stock

Neuphoria Therapeutics Inc. (NEUP) is a Healthcare stock trading at $3.95 (as of 2026-08-21), with a market capitalization of $21.35M and a trailing P/E of 7.9. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Neuphoria Therapeutics Inc. is a clinical-stage biotechnology company developing therapies for people affected by neuropsychiatric disorders. The company was founded on December 23, 2024 and is headquartered in Burlington, Massachusetts.

Understand Neuphoria Therapeutics Inc.: how it makes money

Neuphoria Therapeutics develops clinical-stage therapies for people with neuropsychiatric disorders, and it is currently reporting 0.0B in revenue, so the business is still in development rather than product sales.

As a clinical-stage biotechnology company focused on developing therapies for neuropsychiatric disorders, its profit model depends on progressing clinical development and ultimately creating therapies that can generate revenue.

Business quality (Weak): New, clinical-stage company with limited investor-visible operating metrics, no reportable segments provided, and currently deep operating losses, so near-term fundamentals are dominated by development execution rather than established revenue drivers.

Bull case

  • Clear therapeutic focus: It is dedicated to developing therapies for individuals affected by neuropsychiatric disorders, which defines a specific development objective.
  • Early stage but purposeful pathway: Being clinical-stage biotech implies the company is actively building toward therapies through its development efforts, rather than relying on existing product sales.

Bear case

  • No current revenue reported: The latest provided period shows revenue of 0.0B, indicating the company is not yet generating operating revenue from products.
  • Heavily loss-making operations: Operating margin is reported at -650.8% for 2026-03-31, reflecting substantial operating losses during the development period.
Valuation — source: SEC EDGAR (first-party)
Price$3.95
Market Cap$21.35M
P/E Ratio7.9
EV / EBITDA0.9
Price / Book0.73
Price / Sales1.38
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$15.65M
Net Margin-2.4%
Revenue Growth (YoY)-98.8%
EPS Growth (YoY)-101.4%
Financial Health — source: SEC EDGAR
Altman Z-Score-7.28 (distress)
Valuation vs Sector & Industry
Stock P/E7.9
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.0
vs Sector-63.7%
vs Industry-53.6%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderLynx1 Capital Management LP ($3.56M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOSpyridon Papapetropoulos
Employees8
CountryUS
IPO Date2021-12-16

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • TherapeuticsMD, Inc. (TXMD)
  • ABVC BioPharma, Inc. (ABVC)
  • Marker Therapeutics, Inc. (MRKR)
  • Allarity Therapeutics, Inc. (ALLR)
  • Biofrontera Inc. (BFRI)
  • Cocrystal Pharma, Inc. (COCP)
  • Celularity Inc. (CELU)
  • Tempest Therapeutics, Inc. (TPST)
NEUP earnings history · NEUP institutional & insider holders · NEUP KPIs & operating metrics · NEUP financials · NEUP investor presentations & press releases · NEUP SEC filings · NEUP peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.